UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2007

SYNVISTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-16043	13-3304550
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

221 West Grand Avenue

Montvale, New Jersey 07645

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (201) 934-5000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

On October 1, 2007, Synvista Therapeutics, Inc., a Delaware corporation (the “Company”), announced that Dr. Carl Mendel, MD, has joined the Company as its Vice President of Clinical Development and Chief Medical Officer, commencing on October 1, 2007. Dr. Mendel will receive an annual salary of $265,000 and will be eligible to receive an annual cash bonus based on predetermined milestones of up to 20% of his annual salary. In addition, upon commencement of his employment with the Company, Dr. Mendel will be granted options to purchase 70,000 shares of the Company’s common stock at an exercise price equal to the closing price of the common stock on the grant date. Dr. Mendel will be an at-will employee of the Company.

A copy of the press release announcing Dr. Mendel’s appointment is attached hereto as Exhibit 99.1 and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d)

Exhibits.

99.1	Press Release dated October 1, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	SYNVISTA THERAPEUTICS, INC.

Dated: October 1, 2007	By:	/s/ Noah Berkowitz, M.D., Ph.D.
		Noah Berkowitz, M.D., Ph.D.
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number

Description

99.1	Press Release dated October 1, 2007.

Synvista Therapeutics, Inc. 8-K